

1c811 U.S. PTO
05/25/00

lf-26-00

A

By Express Mail #EL350351095US

Attorney Docket No.: 4910-3

Check box if applicable: ☐ DUPLICATE

UTILITY PATENT APPLICATION TRANSMITTAL

Submit an original and a duplicate for fee processing

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

1c530 U.S. PTO
09/578656
05/25/00

Assistant Commissioner for Patents
BOX PATENT APPLICATION
Washington, DC 20231

Dated: May 25, 2000

Sir:

Transmitted herewith for filing is the utility patent application of:

Inventor(s): Hung LI, Hsiu-Mei HSIEH-LI, Jan-Gowth CHANG

For: A Knockout-Transgenic Mouse Model of Spinal Muscular Atrophy

Enclosed are:

1. Transmittal letter (2x) with Fee Computation Sheet
2. General Authorization For Payment of Fees (2x)
3. Title Page, Specification, Claims 1 to 19 & Abstract (28 pages [total number of pages of application])
4. Executed Declaration and Power of Attorney (3 p.)
5. Two sheet(s) of drawing(s) (Figs. 1 to 2)
6. Check for \$ 345 for filing fee
7. Assignment of the invention to **Academia Sinica**
8. Recordation Cover Sheet (PTO-1595)
9. Check for \$40.00 for Assignment Recording Fee
10. Unexecuted Verified Statement to Establish Small Entity Status
11. Return Receipt Postcard

☐ Please charge my Deposit Account No. 03-2412 in the amount of \$_. A duplicate copy of this sheet is enclosed.

[x] The Commissioner is hereby authorized to charge payment of the following fees associated with this application or credit any overpayment to Deposit Acct. No. 03-2412.

[x] Any additional filing fees required under 37 CFR 1.16.

[x] Any patent application processing fees under 37 CFR 1.17

By Express Mail #EL350351095US

- [x] The issue fee set in 37 CFR 1.18 at 3 months from mailing of the Notice of Allowance, pursuant to 37 CFR 1.311 (b) provided the fee has not already been paid by check.
- [x] Any filing fees under 37 CFR 1.16 for presentation of extra claims.
- [x] Priority is claimed for this invention and application, corresponding applications having been filed in **United States** on **May 28, 1999**, No. **60/136,520**.

Respectfully submitted,
COHEN, PONTANI, LIEBERMAN & PAVANE

By: Kent H. Cheng
Kent H. Cheng
Reg. No. 33,849

551 Fifth Avenue, Suite 1210
New York, New York 10176
Tel: (212) 687-2770
Fax: (212) 972-5487

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY
STATUS (37 CFR 1.9(f) and 1.27(b)) - NONPROFIT ORGANIZATION**

Applicant or Patentee: Hung LI, Hsiu-Mei HSIEH-LI, Jan-Gowth CHANG
Attorney's Docket No.: 4910-3
Serial or Patent No.: Not Yet Assigned
Filed or Issued: Concurrently Herewith
Title: A KNOCKOUT-TRANSGENIC MOUSE MODEL OF SPINAL MUSCULAR ATROPHY

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF NONPROFIT ORGANIZATION: Academia Sinica

ADDRESS OF NONPROFIT ORGANIZATION: 128, Sec. 2, Academia Sinica Road, Nankang, Taipei 115, Taiwan R.O.C.,

TYPE OF NONPROFIT ORGANIZATION:

☐ University Or Other Institution Of Higher Education

☐ Tax exempt under Internal Revenue Service Code (26 u.s.c. 501(a) and 501(c)(3))

☐ Nonprofit Scientific or Educational Under Statute of State of the United States of America
(Name of State _____)
(Citation of Statute _____)

☐ Would qualify as tax exempt under Internal Revenue Service Code (26 u.s.c. 501(a) and 501(c)(3)) if located in the United States

☒ Would Qualify as Nonprofit Scientific or Educational Under Statute of State of the United States of America if located in the United States
(Name of State _____)
(Citation of Statute 26 U.S.C. 501(c)(3))

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the U. S. Patent and Trademark Office regarding the invention described in:

☒ the specification filed herewith with title listed above.
☐ the application identified above.
☐ the patent identified above.

I hereby state that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention. If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention must file separate statements as to their status as small entities, and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern or organization having any rights in the invention is listed below:

☐ no such person, concern, or organization exists.
☐ each such person, concern or organization listed below

FULL NAME: _____
ADDRESS: _____
☐ INDIVIDUAL ☐ SMALL BUSINESS CONCERN ☐ NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING: _____
TITLE IN ORGANIZATION OF PERSON SIGNING: _____
ADDRESS OF PERSON SIGNING: _____
SIGNATURE: _____ DATE: _____

APPLICATION FOR UNITED STATES

LETTERS PATENT

A Knockout-Transgenic Mouse Model of Spinal Muscular Atrophy

Inventors:

Hung LI
Hsiu-Mei HSIEH-LI
Jan-Gowth CHANG
Yuh-Jyh JONG
Mei-Hsiang WU
Chang-Hai TSAI

RELATED APPLICATIONS

This application claims priority from U.S. Provisional Patent Application Serial Number 60/136,520 which was filed on May 28, 1999.

5

BACKGROUND OF THE INVENTION

Field of the Invention

The present invention relates to a mouse model for spinal muscular atrophy, or SMA, and to methods of making and using said mouse model. Particularly, the invention pertains to a genetically engineered mouse model which genotypically and phenotypically mimics human patients with spinal muscular atrophy. Said mouse model is useful in developing and evaluating various methods for diagnosing and treating human SMA patients.

Description of the Related Art

Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of anterior horn cells of the spinal cord leading to muscular paralysis with muscular atrophy. Clinical diagnosis of the disease is based on progressive symmetric weakness and atrophy of the proximal muscles. Affected individuals are usually classified into three groups according to the age of onset and progression of the disease. Type I SMA, also known as Werdnig-Hoffman disease, is most severe, and affected children usually show SMA symptoms before 6 months of age and rarely live beyond the age of 2 years. Type II and Type III SMA are less severe, and the onset of symptoms varies between 6 months and 17 years of

age [see references 1-4]. SMA is one of the most common fetal autosomal recessive diseases, with a carrier rate of 1-3% in the general population and an incidence of 1 in 10,000 newborns [see references 5 and 8].

The pathological abnormality of SMA is the loss of motor neurons in the anterior horn of the spinal cord and in the brain stem, but the brain cortex is usually unaffected [see reference 9]. All three types of SMA are characterized by a marked decrease in deep reflexes and a diffused symmetric weakness of proximal muscles. Electromyographic analyses show muscle denervation with neither sign of sensory denervation nor major change in the motor nerve conduction velocity. Muscle denervation with atrophic fibers has been confirmed by muscle biopsy. Fiber groupings show features of muscle immaturity, suggesting an arrest in development [see references 10 and 11].

Irrespective of clinical severity, molecular analysis has shown that both types of the disease, whether it has a severe early onset or a mild late onset, are linked to the same chromosome locus 5q13, suggesting genetic homogeneity [see references 12-15]. Positional cloning strategies have led to the identification of two candidate genes for SMA, namely, survival motor neuron (*SMN*) and neuronal apoptosis inhibitory protein (*NAIP*) [see references 16 and 17]. These two genes are positioned within a complex region that is duplicated on the long arm of chromosome 5, resulting in two copies of *NAIP* (i.e., *NAIP^T* and *NAIP^C*) and two copies of *SMN* (i.e., *SMN^T* and *SMN^C*) in the human genome [see reference 18]. Deletion of *NAIP* exon 5 was found in 22-60% of type I SMA patients and in 5-18% of type II and III patients [see references 19-22]. Such deletion is also found in 3% of normal individuals, suggesting the gene is non-essential for motor neuron survival. In contrast, 95% of SMA patients carry homozygous deletions of *SMN^T* regardless of phenotypic severity [see references

16, 19-21]. Telomeric *SMN* (*SMN^T*) and centromeric *SMN* (*SMN^C*) differ only in five nucleotides, none of which results in an amino acid change. Rarely, asymptomatic individuals show homozygous *SMN^T* deletion [see references 19, 22-24]. *SMN^C* deletion was found in 2-5% of normal populations [see references 16, 22]. Several intragenic mutations have been found in SMA patients with specific disruption in *SMN^T*, providing further evidence that *SMN^T* is associated with SMA [see references 16, 18, 25-27]. The *SMN^C* gene is also expressed in SMA patients, but expression pattern is different from that of *SMN^T*. Most *SMN^C* transcripts lack exons 3, 5 or 7, particularly 7, while most *SMN^T* transcripts appear to be full-length mRNAs [see references 28-29]. Dosage analysis shows that the *SMN* protein is significantly decreased in Type I patients [see references 30-31].

The *SMN* gene shows no homology to any previously identified genes. Recently, the *SMN* protein has been identified as one of the heterogeneous ribonucleoprotein U-associated proteins. The subsequent immunohistochemical analysis localized the *SMN* protein in a specific nuclear structure called gems [see references 32-33]. Based on the association of the gems and coiled bodies, a role of the *SMN* protein in RNA metabolism has been suggested and confirmed in an *in vitro* analysis [see reference 34]. Because the *SMN* gene is ubiquitously expressed in neuronal and non-neuronal tissues [see reference 16], the mechanism involved in specific degeneration of motor neurons, a characteristic feature of SMA, remains to be elucidated.

In addition to the lack of understanding of the pathophysiology of spinal muscular atrophy, there is no specific treatment currently available for SMA patients. Although transgenic mouse models have been utilized in studying various human diseases, including development of methods for diagnosis and treatment, no one has taught or suggested

that a useful mouse model can be built for spinal muscular atrophy by knocking out the native mouse *Smn* gene and then rescuing the mouse with human *SMN^C* gene inserted into the mouse genome.

The applicant hereby discloses an invention of a mouse model for spinal muscular atrophy. Said mouse model is genotypically and phenotypically mimic to human SMA patients and can be used to understand the pathophysiology of SMA and to develop methods of diagnosis and treatment of the disease. Part of the present invention was published in "A mouse model for spinal muscular atrophy", *Nature Genetics* 24, 66-70 (2000), the entire content of which is expressly incorporated herein.

Cited references:

1. Wohlfart, G., Fex, J., Eliasson, W.S. Hereditary proximal spinal muscular atrophy: a clinical entity simulating progressive muscular dystrophy. *Acta Psychiatr Neuro Scand* 30, 395-406 (1995).
2. Kugelberg, E, & Welander, L. Heredo-familial juvenile muscular atrophy simulating muscular dystrophy. *Arch Neuro Psych* 75, 500-509 (1956).
3. Dubowitz, V. Infantile muscular atrophy: a prospective study with particular reference to a slowly progressive variety. *Brain* 87, 707-718 (1964).
4. Pearn, J., Gardner-Medwin, D., Wilson, J.A. Clinical study of chronic childhood spinal muscular atrophy: a review of 141 cases. *J Neurol Sci* 37, 227-248 (1978).
5. Pearn J. The gene frequency of acute Werdnig-Hoffmann disease (SMA type I): a total population survey in north-east England. *J Med Genet* 10, 260-265 (1973).

6. Pearn, J. Incidence, prevalence, and frequency studies of chronic childhood spinal muscular atrophy. *J Med Genet* 15, 409-413 (1978).
7. Cziezel, A. & Hamula J. Selective and non-selective susceptibility for muscle fiber types. *J. Med Genet* 26, 761-763 (1989).
8. Roberts DF, Chavez J, Court SDM. The genetic component in child mortality. *Arch Dis Child* 45, 33-38 (1970).
9. Shishikarak, K., Hara, M., Sasaki Y & Misagik, A neuropathologic study of Werdnig-Hoffmann disease with special reference to the thalamus and posterior roots. *Acta Neuropathol* 60, 99-106 (1983).
10. Engel, W.K. Selective and non-selective susceptibility for muscle fiber types. *Arch Neurol* 22, 97-117 (1970).
11. Fidzianska, A. Ultrastructural changes in muscle in spinal muscular atrophy-Werdnig-Hoffmann's disease. *Acta Neuropathol* 27, 247-256 (1974).
12. Brzustowicz, L.M. *et al.* Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q 11.2-11.3 *Nature* 344, 540-541 (1990).
13. Gilliam, T.C. *et al.* Genetic homogeneity between acute and chronic forms of spinal muscular atrophy. *Nature* 345, 823-825 (1990).
14. Melki, J. *et al.* Gene for chronic proximal spinal muscular atrophies maps to chromosome 5q. *Nature* 344, 767-768 (1990a).
15. Melki, J. *et al.* Mapping of acute (type I) spinal muscular atrophy to chromosome 5q12-q14. *Lancet* 336, 271-273 (1990b).

16. Lefebvre, S. *et al.* Identification and characterization of a spinal muscular atrophy-determining gene. *Cell* 80, 155-165 (1995).
17. Roy, N. *et al.* The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. *Cell* 80, 167-178 (1995).
18. Lefebvre, S., Bürglen, L., Frézal, J., Munnich, A. & Melki, J. The role of the SMN gene in proximal spinal muscular atrophy. *Hum Mol Genet* 7, 1531-1561 (1998).
19. Velasco E., Velero, C., Valero, A., Moreno, F. & Hernandez, C.C. Molecular analysis of the SMN and MAIP genes in Spanish spinal muscular atrophy (SMA) families and correlation between number of copies of CBCD 541 and SMA phenotype. *Hum Mol Genet* 5, 2570263 (1996).
20. Rodriguess, N.R. *et al.* Gene deletions in spinal muscular atrophy. *J Med Genet* 33, 93-96 (1996).
21. Burglen L. *et al.* The gene encoding P44, a subunit of the transcription factor TFIIH, is involved in large-scale deletions associated with Werdnig-Hoffman disease. *Am J Hum Genet* 60, 72-79 (1997).
22. Chang, J.G. *et al.* Molecular analysis of survival motor neuron (SMN) and neuronal apoptosis inhibitory protein (NAIP) genes of spinal muscular atrophy patients and their parents. *Hum Genet* 100, 577-581 (1997) .
23. Hahnen, E. *et al.* Molecular analysis of candidate genes on chromosome 5q 13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of SMN gene in unaffected individuals. *Hum Mol Genet* 4, 1927-1933 (1995).
24. Cobben, J.M. *et al.* Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. *Am J Hum Genet* 57, 805-808 (1995).

25. Campbell, L., Potter, A., Ignatius, J., Dubowitz, V. & Davies, K. Genomic variation and gene conversion in spinal muscular atrophy: Implications for disease process and clinical phenotype. *Am J Hum Genet* 61, 40-50 (1997).
26. Bussaglia, E. *et al.* A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients. *Nature Genet* 11, 335-337 (1995).
27. Parsons, D.W., McAnchew, P.E., Innaccone, S.T., Mendel, J.R., Burghes, A.H.M. & Prior, T.W. Intragenic telSMN mutations; frequency, distribution, evidence of a founder effect, and modification of the spinal muscular atrophy phenotype by cenSMN copy number. *Am J Hum Genet* 63, 1712-1723 (1998).
28. Gennarelli, M. *et al.* Survival motor neuron gene transcript analysis in muscles from spinal muscular atrophy patients. *Biochem Biophys Res Commun* 213, 342-348 (1995).
29. Chang, J.G. *et al.* Analysis of the mRNA products of the survival motor neuron (SMN) gene in peripheral blood mononuclear cells of normals. Carriers and SMA patients. *Am J Hum Genet* 59 (suppl), A252-1457 (1996).
30. Lefebvre, S. *et al.* Correlation between severity and SMN protein level in spinal muscular atrophy. *Nature genet* 16, 265-269 (1997).
31. Burlet P. *et al.* The distribution of SMN protein complex in human fetal tissues and its alteration in spinal muscular atrophy. *Hum Mol Genet* 7, 1927-1933 (1998).
32. Liu, Q., Fischer, V., Wang, F. & Dreyfuss, G. The spinal muscular atrophy disease gene product. SMN and its associated protein SIP1 are in a complex with spliceosomal snRNP protein. *Cell* 90, 1013-1021 (1997).

SUMMARY OF THE INVENTION

The present invention discloses a transgenic mouse model for spinal muscular atrophy. The genome of said mouse model carries at least one copy of human *SMN^C* gene and a mutation that knocks out the native mouse *Smn* gene. Human *SMN^C* gene is functional in a murine background and compensates for the loss of the *Smn* protein as evidenced by the rescue of the early lethality phenotype caused by the *Smn* knockout. The phenotypes of said mouse model are similar to those of SMA patients and can be subgrouped into three types according to their phenotypic severity. All these 3 types may be identified from at least two transgenic founder lines crossed with *Smn* knockout mice, indicating that these phenotypes are not caused by the position effect of the transgene. According to the present invention, the mouse model can be used for studying the pathophysiology of the disease. For example, using this mouse model, applicants have discovered that the severity of SMA-associated symptoms is proportionally related to the decrease in *SMN* protein production. This discovery is consistent with the prior hypothesis that the intact *SMN* protein is most important for phenotypic expression of the disease.

It is also an aspect of the present invention to use the transgenic mouse model for testing efficacy of various present and future therapeutic methods for spinal muscular atrophy, including drug and gene therapies as well as other therapeutic technologies. Drug therapy refers to the use of one or more chemical compounds to correct or alleviate pathological conditions at, in most cases, the cellular level, while genetic therapy generally refers to the method of correcting the underlying genetic defect at the DNA level, that is, by replacing the incorrect DNA sequences with the correct ones. Transgenic mice have been used

for testing therapeutic efficacy for a wide variety of diseases and the general protocol is well known. Basically, the testing includes two steps. The first step is applying a therapy or a combination of therapies to a mouse model for a particular disease. The second step is to determine whether the pathological conditions characteristic of said disease is alleviated due to the application of the therapy. The therapeutic efficacy of a therapy can then be determined by comparing the pathological conditions shown in the same mouse model before and after applying the therapy, or by comparing the pathological conditions shown in the treated mice and untreated control mice.

Another aspect of the present invention is the use of the mouse model for testing the accuracy and sensitivity of diagnostic methods for spinal muscular atrophy. Specifically, said mouse model provides a convenient positive control necessary for developing and testing any diagnostic methods for spinal muscular atrophy.

It is further understood that, upon obtaining the mouse model of the present invention, people with ordinary skill in the art will be able to use the model for various practical purposes by making necessary variations and implementing certain details specific to the SMA mouse model.

In summary, one of the objectives of the present invention is to provide a mouse model for human spinal muscular atrophy. Another objective is to provide a method of understanding the pathophysiology of spinal muscular atrophy. A further objective is to provide a method of screening and testing new therapies for spinal muscular atrophy treatment and a method of designing and evaluating better means of diagnosis of spinal muscular atrophy.

Other objects and features of the present invention will become apparent from the following detailed description considered in conjunction with the accompanying drawings. It is to be understood, however, that the description and drawings are provided solely for purposes of illustration and not as a definition of the limits of the invention, for which
5 reference should be made to the claims.

The various features of novelty which characterize the invention are pointed out with particularity in the claims annexed to and forming a part of the disclosure. For a better understanding of the invention, its operating advantages, and specific objects attained by its use, reference should be had to the drawing and descriptive matter in which there are illustrated and
10 described preferred embodiments of the invention.

BRIEF DESCRIPTION OF THE DRAWINGS

In the drawings, like reference characters denote similar elements throughout the several views:

5 FIG. 1 is a diagram depicting the disruption of the mouse *Smn* gene with a targeting vector and the resulting knockout allele.

FIG. 2 is a diagram depicting the gene organization in the human *SMN* locus.

Continued on next page

DETAILED DESCRIPTION OF THE PRESENTLY PREFERRED EMBODIMENTS

Isolation of mouse *Smn* genomic and human *SMN* BAC clones

The human *SMN* cDNA fragments A (covering exons 1-4) and C (covering
 5 exons 6-8) were used as probes to screen the mouse 129/Sv genomic (commercially available
 from Strategene) and human BAC libraries (available from Genome System). Three positive
Smn genomic clones were isolated and subcloned into the pBS vector (available from
 Strategene). Four (4) positive BAC clones were classified as *SMN^C* or *SMN^T* by PCR-RFLP
 analysis as described by Cobben, J.M. *et al.* "Deletions of the survival motor neuron gene in
 10 unaffected siblings of patients with spinal muscular atrophy." *Am J Hum Genet* 57, 805-808
 (1995).

Generation of *Smn* knockout and *SMN^C* transgenic mouse

To generate the *Smn* homologous recombination construction, a 4.6 kb *Bam*HI
 5 fragment and a 0.6 kb *Nde*I fragment (covering *Smn* cDNA exons 2-8) of the mouse genomic
 clone MSG24-2, were subcloned into the *Bam*HI and *Cla*I sites of pGKKOV vector, see
 Schrank, B. *et al.* "Inactivation of the survival motor neuron gene, a candidate gene for human
 spinal muscular atrophy, leads to massive cell death in early mouse embryos." *Proc. Natl. Acad.*
Sci. USA 94, 9920-9925 (1997). The resulting construct, pGKKO-*Smn*, underwent a deletion of
 20 a 1.6 kb segment which includes the *Smn* exon 7. The final pGKKO-*Smn* construct was
 linearized with *Not*I and then electroporated into E14 TG2a ES cells, see Hopper, M., Handy,
 K., Handyside A., Hunter, S., & Monk, M. "HPRT-deficient (Lesch-Nyhan) mouse embryos
 derived from qermline colonization by culture cells." *Nature* 326, 292-295 (1987). Selection and

screening of ES cells for homologous recombination were performed as previously described by Schrank, B. *et al.* "Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos." *Proc. Natl. Acad. Sci. USA* 94, 9920-9925 (1997). The positive ES cells were then injected into C57BL/6

5 blastocysts by a standard procedure as described by Hogan, B., Beddington, R., Costantini, F. & Lacy, E. "Manipulating the mouse embryo. A laboratory manual." (1994), Cold Spring Harbor laboratory, Cold Spring Harbor, New York,.

To generate *SMN^C* transgenic mice, the vector sequence of *SMN* BAC clone 7C was excised with *NotI* and a resulting 115 kb DNA fragment (insert DNA), which encompasses the human centromeric *SMN* (*SMN^C*) region including part of *NAIP^C* and intact *H4F5*, was electroeluted from agarose gel. The insert DNA was diluted to 2 ng/1 in 10 mM Tris-HCl pH7.4, 01 mM EDTA, and microinjected into FVB/N mouse male pronuclei as described by Hogan, B., Beddington, R., Costantini, F. & Lacy, E. Manipulating the mouse embryo. A laboratory manual (1994), Cold Spring Harbor laboratory, Cold Spring Harbor, New York.

Following the microinjection, five independent transgenic mice founder lines (F0) were generated in this particular case. The F0 mice appeared normal and the transgene was transmitted to F1 progenies. The F1 mice, who have the human transgene *SMN^C* and are heterozygous for the mouse *Smn* locus (*Smn^{+/-}SMN^C*), were obtained from crossing the F0 founders to *Smn^{+/-}* mice. Then, transgenic mice homozygous for the knockout alleles, i.e.,

20 *Smn^{-/-}SMN^C*, were generated by F1 crossing with *Smn^{+/-}* mice or F1 intercrossing.

Genotyping of *Smn* knockout and *SMN^C* transgenic mice

Smn knockout mice were genotyped by Southern blot or PCR analysis. Probes A and B, as shown in FIG. 1, were used in Southern blot analysis of mouse genomic DNA digested with *NheI* or *EcoRV*. Three primers were prepared for the PCR analysis: S1 (5'-ATAACACCACCACTCTTACTC-3'), S2 (5'-GTAGCCGTGATGCCATTGTCA-3'; 1,150 bp), H1 (5'-AGCCTGAAGAACGAGATCAGC-3'; 950 bp). S1 and S2 were used for detection of the wild type alleles while S1 and H1 were used for detection of the knockout alleles. Further, another three sets of PCR primers were prepared for identifying transgenic mice: (1) 5'-ACTGCAACCTCCTGGGTTCAAGTG-3' and 5'-CAGTTCGAGACCAGCCTGACCAAT-3', probing the 5' untranslated region of *SMN*; (2) 5'-CGAATCACTTGAGG GCAGGAGTTTG-3' and 5'-AACTGGTGGACATGGCTGTTCATTG-3', probing the 3' end of BAC clone; and (3) 5'-AAACCAGTCGGGCACAATACCTAGC-3' and 5'-TATGCTGATTGAAGGGAGGGGTGC-3', probing the 5' end of the BAC clone. The number of transgene copies in the transgenic mouse genome was determined in a Southern blot analysis by the amount of the probe (spanning *SMN* cDNA exons 3 and 4) that was hybridized to *PstI*-digested mouse genomic DNA.

Phenotypic characterization of the *Smn*^{-/-}*SMN^C* mice

While the heterozygous *Smn*^{+/-}*SMN^C* mice showed no gross morphological difference in comparison with normal mice, the *Smn*^{-/-}*SMN^C* mice showed a wide range of symptoms, from early death to mild abnormalities. Grossly, these mice had lower body weights and shorter tails in comparison with their normal and heterozygote siblings, and could be classified into three groups according to their life span. Type I mice, the most severe type, died around day 10 without furry hair development; type II mice showed poor activity and

died in 3-4 weeks; and type III mice survived and bred normally but had shorter and enlarged tails. About 50% of the type III mice developed chronic necrosis starting from the tip towards the root of the tail until the tail fell off. Such chronic necrosis was also be triggered when part of the tail is cut off for genotype analysis. The *Smn*^{-/-}*SMN*^C mice of different types appeared in the same litter of identical parents.

Blastocyst culture

Blastocysts from *Smn*^{+/-} mating were flushed out from the uterus on day 3.5 post coitum and cultured in Dulbecco's modified Eagle's medium (from Gibco, BRL) supplemented with 15% fetal bovine serum, 0.05 mM β -mercaptoethanol and 1 mM glutamine at 37° C in 5% CO₂. Individual blastocysts were cultured in separate plates coated with 0.15% gelatin in either the presence or the absence of 10³ units of LIF, see Hendrey, J., Lin D., and Dziadek, M. "Developmental Analysis of the Hba Mouse Mutation: Effects on mouse peri-implantation development and identification of two candidate genes." *Develop Biol.* 172, 253-263 (1995). Embryo morphology was monitored 3 or 4 times daily, and non-attached embryos were harvested into 5 μ l of alkaline lysis buffer (200 mM KOH, 50 mM dithiothreitol) immediately after observing abnormal morphology. After 20 min incubation at 65 °C, 5 μ l neutralization solution (900 mM Tris-HCl, pH 8.3, 300 mM KCl, 200 mM HCl) was added to the harvested samples. 5 μ l aliquots of the lysed and neutralized sample was taken for genotyping by PCR analysis as described by Zhang, L. *et al.* "Whole genome amplification from a single cell: Implications for genetic analysis." *Proc. Natl. Acad. Sci. USA* 89, 5847-5851 (1992). On the other hand, the attached and expanded embryos were scraped off the bottom of the plates after a 4-day culture and, in a similar fashion, lysed and prepared for PCR analysis.

Analysis of *SMN^C* transgene expression in mice.

Reverse transcription from total RNA was carried out using a random primer 5'-TN₁₀-3' and MMLV reverse transcriptase (from Promega). The resulting single-stranded cDNA was then PCR-amplified using one or three pairs of primers that covers the entire *SMN* coding region. The first primer pair, amplifying the fragment from the 5' untranslated region to exon 4, was a forward primer 5'-CGCTGCGCATCCGCGGGTTTGCTATGGC-3' (also referred as P1) and a reverse primer 5'-TCCCAGTCTTGGC-CCTGGCAT-3'. The second primer pair, amplifying exons 4-6, was a forward primer 5'-AACATCAAGCCCAAATCTGC-3' and a reverse primer 5'-GCCAGTATGATAGCCACTCATGTACCATG-3'. The third primer pair, amplifying exons 6-8 was a forward primer 5'-CTCCCATATGTCCAGATTCTCTTGATGATGC-3' and a reverse primer 5'-ACTGCCTCACCACCGTGCTGG-3' (also referred as P6). In addition, P1 and P6 were used to amplify the full-length *SMN* cDNA.

The human *SMN^C* transgene in the *Smn^{-/-}SMN^C* mice were found expressed extensively in all the tissues analyzed. Like SMA patients, alternative splicing involving exons 3, 5 and 7 of the human *SMN^C* gene was also observed in these mice. A majority of the transcripts also lacked exon 7. Transcripts without exon 3 or exon 5, and the full-length transcripts, were detected to a lesser extent. Among the three types of *Smn^{-/-}SMN^C* mice, the ratio of full length transcripts versus alternatively spliced transcripts varied slightly. The early onset mice always produced fewer full-length transcripts, while mice with mild symptoms generally produced more full-length transcripts.

Subcellular fractionation

Fresh frozen spinal cord and skeletal muscle samples (500 mg) from different transgenic mice were fractionated as described by Schreiber, E., Matthias, P., Muller, M.M. & Schaffner, W. "Rapid detection of octamer binding proteins with 'mini-extracts' prepared from a small number of cells." *Nucleic Acids Res.* **17**, 6419 (1989). The tissues were homogenized with a tight-fitting glass pestle in ice-cold buffer A (10 mM Hepes, pH 7.9, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, 0.5 mM PMSF, 2 g/ml leupeptin, 2 g/ml pepstatin) with 0.5% Nonidet P-40 and kept on ice for 15 minutes. The nuclei were pelleted by centrifugation at 800g for 3 minutes, and resuspended by trituration in 100 μ l of buffer B (20 mM Hepes, pH 7.9, 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 2 g/ml leupeptin, 2 g/ml pepstatin), kept on ice for 15 minutes and then re-centrifuged at 15,000g for 10 minutes at 4° C. The supernatant (soluble nuclear extract) was removed and the insoluble nuclear pellet was sonicated in a sonication buffer (100 mM Tris-HCl, pH 7.4, 1% SDS, 5 mM EDTA, 1 mM DTT, 1 mM PMSF, 2 g/ml leupeptin, 2 g/ml pepstatin).

Western-blot analysis

Anti-human *SMN* antibodies were raised in rabbits against synthetic peptides encoded by parts of human *SMN* exon 7 (aa 279-288) and exon 2 (aa 72-84). Specific antibodies (H2 and H7) from rabbit crude sera were purified with an EAH-Sepharose 4B column (from Pharmacia) according to the manufacturer's instructions.

Protein samples were loaded on a 5% polyacrylamide stacking gel above a 12% separating gel, and electrophoresis was carried out with a discontinuous buffer according to

Laemmli, U.K. "Cleavage of structural proteins during assembly of the head of bacteriophage T4." *Nature* 227, 680-685 (1970). After electrophoresis the proteins were transferred electrophoretically from the gel to a polyvinyl difluoride membrane (from Millipore). The membrane was then blocked in TBST (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) containing 4% BSA for 2 hours at room temperature. The membrane was further incubated with a 1:800 dilution of anti-*SMN* exon 2 (H2) or anti-*SMN* exon 7 (H7) antibody in TBST for 2 hours at room temperature. The membrane was washed for three 20-minutes periods in TBST and was again incubated with a 1:32,000 dilution of an anti-rabbit IgG alkaline phosphatase conjugate (Sigma) in TBST for 1 hour at room temperature. The blot image was developed by adding 1.5% of 5-bromo-4-chloro-3-indoyl phosphate and 3% of nitro blue tetrazolium in a developing buffer (100 mM NaCl, 5 mM MgCl₂, 100 mM Tris-HCl, pH 9.5).

The results of western blot analysis showed that the decrease in the *SMN* protein production correlated proportionally with the severity of SMA-like symptoms in the *Smn*^{-/-} *SMN*^C mice. For example, Type I mice produced the least amount of the *SMN* protein in comparison with type II or type III mice.

Early embryonic lethality caused by the mutation in *Smn*

To create an *Smn* loss-of-function mutation via homologous recombination in mouse ES cells, applicants in this case isolated genomic clones of the mouse *Smn* locus by hybridization screening of an isogenic 129/Sv mouse genomic library using human *SMN* cDNA fragments corresponding to most of the exons as probes. Three clones were obtained which contained this genomic region. One of the clones, MSG24-2, which covers cDNA exons 2 to

8, was used to generate a targeting construct. A 4.6 kb and a 0.6 kb genomic fragments, flanking exon 7, were subcloned into the positive/negative selection targeting vector, pGKKOV, see Li, H., Zeitler, P.S., Valerius, M.T., Small, K. & Potter, S.S. "Gsh-1, an orphan Hox gene, is required for normal pituitary development." *EMBO J.* **15**, 714-724 (1996)), to replace *Smn* exon 7 with the hypoxanthine phosphoribosyl-transferase (HPRT) cassette, see FIG. 1. After the resulting targeting construct, pKOV-Smn, was linearized and electroporated into ES cells, applicants screened a total of 810 HAT/Ganciclovir-resistant ES clones with Southern blot or PCR analysis and, as a result, identified one clone which was heterozygous for *Smn*, i.e., *Smn*^{+/-}. The *Smn*^{+/-} ES cells were then injected into C57 BL/6 blastocysts to obtain germline transmission of the mutant alleles. Mice heterozygous for *Smn* appeared normal. However, no viable homozygous mutant progenies (*Smn*^{-/-}) were obtained from intercrosses. The ratio between heterozygous and wild type mice was approximately 2:1. To examine the timing of development arrest, different stages of embryos from *Smn*^{+/-} crossing were examined and normal ratios of homozygous E 3.5 blastocysts were found. However, there was no homozygotes found after E 6.5. When E 3.5 blastocyst were plated *in vitro*, wild type or heterozygous embryos hatched and attached during the first 1-2 days of culture to form an extended monolayer of polyploid, a giant trophoblast where the round cluster of inner cell mass (ICM) was attached. In contrast, homozygous mutants showed no attachment but extensive cellular degeneration during the first 12-36 hours of culture. This suggests that *Smn* plays an important role during early mouse development.

Histopathological analysis

Mice were scarified with CO₂. Spinal cords and anterior spinal roots were fixed in 4% glutaraldehyde in 0.1 M cacodylate buffer, pH 7.4 for 2 hour at room temperature. After fixation, the tissues were washed in three changes of cacodylate buffer (0.1 M) for at least 20 minutes and then postfixed in 1% osmium tetroxide in 0.1 M cacodylate buffer for 1.5 hours at room temperature. The tissues were dehydrated using graded ethanol (50%, 70%, 90% and four changes of 100%) for 10 minutes each change, and then one change with propylene oxide for 5 minutes, one change with propylene oxide:epikote (1:1) for 1 hour, and lastly one change in epikote overnight at 4° C. The tissues were embedded in fresh epikote in polypropylene capsules and hardened at 60° C for 48-72 hours. The tissues other than spinal cord were placed in 10 volumes of 10% neutral buffered formalin and embedded in paraffin. Serial frozen sections of mouse muscle were stained using histochemical methods including haematoxylin and eosin (H&E), modified Gomori trichrome, NADH-TR, routine ATPase, and ATPase with preincubation at pH 4.6 and 4.3 as described by Dubowitz, V. "Muscle Disorders in Childhood," W.B. Saunders, London (1995). Immunohistochemical staining was carried out according to Lefebvre, S. *et al.* "Correlation between severity and the *SMN* protein level in spinal muscular atrophy." *Nature Genet.* 16, 265-269 (1997).

Histopathological analysis of liver, spleen, kidney, heart, lung and gastrointestinal tract from the *Smn*^{-/-}*SMN*^C mice showed no pathological abnormality.

Pathological analysis of the tail tissue, however, revealed a decrease in muscular fiber, atrophic muscular bundles and subcutaneous edema. The subcutaneous edema was more severe in type III than other types, and it was rare in type I. The short and enlarged tails of type II and III mice show normal number of skeletal segments via X-ray analysis. Occasionally,

5 selective loss thick myelinated fibers, with active axonal degeneration in both anterior and posterior spinal roots. These neurological defects are similar to the pathological features of SMA patients.

CLAIMS

We claim:

1. A transgenic mouse model whose genome contains at least one mutation that substantially reduces expression of the native mouse *Smn* gene and carries at least one human genomic DNA sequence that at least partially compensates for the reduced expression of said *Smn* gene.

2. The transgenic mouse model of claim 1, said mouse model genotypically and phenotypically mimicking human spinal muscular atrophy patients.

3. The transgenic mouse model of claim 1, whose genome contains at least one knockout mutation in the *Smn* gene and carries at least one copy of human *SMN^c* gene.

4. The transgenic mouse model of claim 3, wherein the alleles of said *Smn* gene are homozygous for said knockout mutation.

5. The transgenic mouse model of claim 3, wherein the alleles of said *Smn* gene are heterozygous for said knockout mutation.

6. The transgenic mouse model of claim 3, said mouse genotypically and phenotypically mimicking human spinal muscular atrophy patients.

7. The transgenic mouse model of claim 4, said mouse genotypically and phenotypically mimicking human spinal muscular atrophy patients.

8. A method of generating a transgenic mouse model of spinal muscular atrophy, comprising the steps of:

(a) introducing a mutation in the genome of a mouse to reduce the expression of mouse *Smn* gene; and

(b) introducing a human genomic DNA sequence into the genome of said mouse to rescue said mouse from the conditions created by reduction in *Smn* gene expression.

9. The method of claim 8, wherein said mutation is introduced by replacing *Smn* exon 7 with a hypoxanthine phosphoribosyl-transferase cassette.

10. The method of claim 8, wherein said human genomic DNA sequence comprises a human *SMN^c* region, which includes centromeric *SERF1* and part of centromeric *NAIP*.

11. The method of claim 9, wherein said human genomic DNA sequence comprises a human *SMN^c* region, which includes centromeric *SERF1* and part of centromeric *NAIP*.

12. A method of testing for therapeutic efficacy on spinal muscular atrophy conditions, said method comprising:

(a) applying one or more of therapies to be tested to a transgenic mouse model of claim 6; and

(b) determining whether one or more conditions characteristic of spinal muscular atrophy have changed as a result of application of said therapy or therapies.

13. The method of claim 12, wherein said therapy is gene therapy which corrects genetic defects by changing genomic DNA sequences.

14. The method of claim 12, wherein said therapy is drug therapy which alleviates pathological conditions characteristic of spinal muscular atrophy by using one or more chemical compounds.

15. The method of claim 12, wherein said transgenic mouse model is made according to claim 7.

16. The method of claim 15, wherein said therapy is gene therapy which corrects genetic defects by changing genomic DNA sequences.

17. The method of claim 15, wherein said therapy is drug therapy which alleviates pathological conditions characteristic of spinal muscular atrophy by using one or more chemical compounds.

[illegible]




Fig. 1




Fig. 2

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled

A Knockout-Transgenic Mouse Model of Spinal Muscular Atrophy

the specification of which is attached hereto.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by an amendment, if any, specifically referred to in this oath or declaration.

I acknowledge the duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, Section 119 (a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT International application having a filing date before that of the application on which priority is claimed:

none

I hereby claim the benefit under 35 USC §119(e) of any United States provisional application listed below:

Application(s): **No. 60/136,520** **Filed: May 28, 1999**

I hereby claim the benefit under Title 35, United States Code, §120 or §365(c) of any PCT International application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

none

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

I hereby appoint the following attorneys and/or agents to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

MYRON COHEN, Reg. No. 17,358; THOMAS C. PONTANI, Reg. No. 29,763; LANCE J. LIEBERMAN, Reg. No. 28,437; MARTIN B. PAVANE, Reg. No. 28,337; MICHAEL C. STUART, Reg. No. 35,698; KLAUS P. STOFFEL, Reg. No. 31,668; EDWARD M. WEISZ, Reg. No. 37,257; JULIA S. KIM, Reg. No. 36,567; VINCENT M. FAZZARI, Reg. No. 26,879; ALFRED W. FROEBRICH, Reg. No. 38,887; KENT H. CHENG, Reg. No. 33,849; GEORGE WANG, Reg. No. 41,419; TZVI HIRSHAUT, Reg. No. 38,732, GERALD J. CECHONY, Reg. No. 31,335 and ROGER S. THOMPSON, Reg. No. 29,594.

Address all telephone calls to Kent H. Cheng, Esq. at telephone No. (212) 687-2770.

Address all correspondence to:
Kent H. Cheng, Esq.
Cohen, Pontani, Lieberman & Pavane
551 Fifth Avenue, Suite 1210
New York, New York 10176

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Sole or First Inventor: Hung LI

Inventor's signature: Hung Li

Dated: 5/19/2000
Month/Day/Year

Residence: **7F, 11-1, Alley 2, 61 Lan, Sec. 2, Academia Road
Nankang, Taipei, 115, Taiwan, R.O.C.**

Citizenship: **Taiwan, R.O.C.**

Post Office Address: **7F, 11-1, Alley 2, 61 Lan, Sec. 2, Academia Road
Nankang, Taipei, 115, Taiwan, R.O.C.**

